The QualityStocks Daily Friday, July 26th, 2024

Today's Top 3 Investment Newsletters

QualityStocks(WINT) $8.2900 +151.98%

360 Wall Street(BFI) $0.4205 +97.33%

Premium Stock Alerts(CREV) $9.0500 +46.68%

The QualityStocks Daily Stock List

Windtree Therapeutics (WINT)

QualityStocks, TraderPower, MarketBeat, The Stock Dork, StockMarketWatch, Wall St. Warrior, StreetInsider, Small Caps, MarketClub Analysis, InvestorsUnderground and InvestorPlace reported earlier on Windtree Therapeutics (WINT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Windtree Therapeutics Inc. (NASDAQ: WINT) is a medical device and clinical-stage biotechnology firm that is engaged in developing therapies for treating cardiovascular and acute pulmonary ailments.

The firm has its headquarters in Warrington, Pennsylvania and was founded in 1992, on November 6th by James S. Kuo and Evan Myrianthopoulos. Prior to its name change in April 2016, the firm was known as Discovery Laboratories Inc. The firm operates in the healthcare sector, under the biotech and pharma sub-industry and serves consumers in the U.S.

The enterprise is party to a collaboration agreement with the University of Milan-Bicocca, which entails discovering and developing new SERCA2a compounds for treating acute and chronic human heart failure. The enterprise is a subsidiary of Lee’s Pharmaceutical Holdings Ltd.

Windtree Therapeutics’ product pipeline is made up of a formulation developed for treating genetically associated hypertension which is known as Rostafuroxin and is currently undergoing phase 2 clinical trials; a lyophilized surfactant indicated for treating lung injuries caused by the coronavirus infection; an aerosolized surfactant indicated for the treatment of respiratory distress syndrome in premature infants dubbed Aerosurf, which is currently undergoing phase 2 clinical trials; and a drug formulation developed for treating early cardiogenic shock and acute decompensated heart failure dubbed Istaroxime, which is in phase 2a and 2b clinical trials.

The firm recently reported their financial results for the 2021 first quarter, which show that it expanded the participating cites and countries for its istaroxime clinical study and extended their collaboration with the University of Milan-Bicocca. The firm’s CEO noted that they were also focused on developing the business and would continue to advance their current and planned activities, which is bound to bring in more investors into the firm.

Windtree Therapeutics (WINT), closed Friday's trading session at $8.29, up 151.9757%, on 48,574,408 volume. The average volume for the last 3 months is 52,968 and the stock's 52-week low/high is $2.81/$30.06.

Energous Corporation (WATT)

MarketClub Analysis, MarketBeat, StockMarketWatch, BUYINS.NET, Schaeffer's, InvestorPlace, TraderPower, The Street, Jason Bond, Stock Gumshoe, Marketbeat.com, StreetInsider, Barchart, 24/7 Trader, Investing Futures, Trading Concepts, Daily Trade Alert, Wall Street Daily, Microcapmillionaires, StreetAuthority Daily, QualityStocks, InvestorsUnderground, Money Morning, One Hot Stock, Promotion Stock Secrets, Zacks, The Best Newsletters, TopStockAnalysts, Uncommon Wisdom, Wealth Daily, WealthMakers and PCG Advisory reported earlier on Energous Corporation (WATT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Energous Corporation (NASDAQ: WATT) (FRA: 116) is a development stage technology firm that is engaged in the development of technology that can allow wireless charging and powering of electronic devices.

The firm operates in the industrials sector, under the electrical equipment sub-industry. Its technology powers devices by encircling them with a 3D pocket of energy formed by radio frequencies.

The company provides transmitters, amplifiers and power receivers for wireless charging applications which include asset trackers, hearing aids, hearables, fitness trackers, wearables and other battery-powered electronics. This is in addition to offering a wireless charging ecosystem dubbed WattUp. This is a software solution that allows users to establish the order with which devices receive power, determine if a device receives a charge based off of battery level thresholds or charge automatically and identify which devices receive power. Unlike current wireless charging systems, this solution delivers usable meaningful power at a distance while enabling users to roam while their device is charging. This saves users from having to remember to place their devices on a mat or plug them in. The company plans to license the product to the mobile and wearable accessory markets, before expanding into other markets such as smartphones and Wi-Fi routers over time.

In conjunction with Atmosic Technologies, the firm recently achieved the industry’s first interoperability for RF (radio frequency) energy harvesting technology. This collaboration will allow the firms to bring to the market cutting-edge products, which not only encourage innovation in the industry but also encourage investments into the firms. This will in turn boost growth.

Energous Corporation (WATT), closed Friday's trading session at $0.925, up 16.5428%, on 260,695 volume. The average volume for the last 3 months is 29,618 and the stock's 52-week low/high is $0.63/$5.60.

Vislink Technologies (VISL)

StockMarketWatch, QualityStocks, Schaeffer's, The Online Investor, StockRockandRoll, PennyStockLocks, Penny Stock 101, BUYINS.NET, Trades Of The Day, StreetInsider, Moleculin Biotech, MarketBeat, InvestorsUnderground and InvestorPlace reported earlier on Vislink Technologies (VISL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Vislink Technologies Inc. (NASDAQ: VISL) (FRA: 15XC) is engaged in the production and distribution of wireless telecommunication equipment such as transmitters, receivers, antennas and amplifiers.

Vislink Technologies Inc. changed its name from xG Technology Inc. in February 2019 and is based in Sarasota, Florida. The firm was founded on August 26, 2002 by Richard L. Mooers, Roger G. Branton and Joseph A. Bobier. Vislink Technologies Inc. serves consumers from Asia, Europe, South and North America and other international markets.

Vislink Technologies develops, manufactures and sells video transmission products under the IMT, RF Central and Nucomm brand names for surveillance markets as well as for the entertainment markets.

The firm also provides microwave radio components, cellular, satellite communication systems and wireless camera systems to national, regional and metropolitan law enforcement agencies, defense organizations and agencies, hosted service providers, live and sports broadcasters, station groups and network owners and broadcasters, under the Vislink brand. Vislink Technologies Inc.’s product portfolio includes an IP satellite data terminal known as AirPro-75; an embedded routing and computing system dubbed SatWare; a dual channel diversity receiver-decoder called ViewBack; an aircraft downlink transmitter dubbed HDX-1100 and an on-camera wireless video transmitter called HCAM.

Vislink Technologies Inc. provides a wide range of high-quality technical solutions. The firm recently received an order valued at over $4 million to supply the U.S. DoD with intelligence, surveillance and reconnaissance receiver accessories and devices, showing just how secure, reliable and high-quality Vislink’s products are.

Vislink Technologies (VISL), closed Friday's trading session at $7.58, up 14.9356%, on 58,191 volume. The average volume for the last 3 months is 1,780 and the stock's 52-week low/high is $2.31/$7.7299.

Susquehanna Community Financial (SQCF)

We reported earlier on Susquehanna Community Financial (SQCF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Susquehanna Community Financial Inc. (OTC: SQCF) is a financial holding firm for Susquehanna Financial Investment Corporation and Susquehanna Community Bank (Bank), engaged in the provision of a range of financial services to individuals and corporate clients.

The firm has its headquarters in West Milton, Pennsylvania and was incorporated in 1920. Prior to its name change in February 2016, the firm was known as West Milton Ban Corp Inc. It operates as part of the banks-regional industry, under the financial services sector. The firm serves consumers around the globe.

The enterprise is an FDIC-insured institution and funds deposited in the bank are insured up to the FDIC’s insurance limit. It accepts various deposit products, including checking and savings accounts, certificates of deposit and individual retirement accounts, as well as money market accounts. It offers lending solutions, such as personal lending; lines of credit; agriculture loans; equipment loans; and small business administration loans, including financing services for purchase or construction of real estate and/or business equipment, as well as debit and credit cards, online and mobile banking, and ATM services. In addition, the enterprise offers residential mortgage loans, home equity loans and other consumer loans; and commercial loans consisting of commercial and industrial, acquisition, construction and development, commercial real estate, and commercial construction loans. Further, it provides treasury management services, such as automated clearing house, remote deposit capture, positive pay and merchant services. The enterprise operates in Lewisburg, Watsontown, West Milton, Mifflinburg, Beaver Springs, Northumberland, and Williamsport, Pennsylvania.

The company remains committed to delivering personalized, relationship-based banking to its customers. This may positively influence investments into the company and bolster its overall growth.

Susquehanna Community Financial (SQCF), closed Friday's trading session at $12.11, even for the day. The average volume for the last 3 months is 200,091 and the stock's 52-week low/high is $10.00/$14.95.

Innovative Industrial Properties Inc. (IIPR)

InvestorPlace, Kiplinger Today, QualityStocks, The Online Investor, Top Pros' Top Picks, Schaeffer's, Daily Trade Alert, The Street, MarketBeat, Wealth Insider Alert, Trades Of The Day, DividendStocks, The Wealth Report, Zacks, TradersPro, StreetInsider, CannabisNewsWire, Stock Up Featured, FreeRealTime, StockMarketWatch, The Street Report, Investopedia, Trading Concepts, Early Bird, CFN Media Group, Stock Gumshoe, Outsider Club, Marketbeat.com, StreetAuthority Daily, TipRanks, VectorVest and Wealth Daily reported earlier on Innovative Industrial Properties Inc. (IIPR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The state of Ohio legalized the medical use of cannabis in 2016, making it the 25th state in the country to do so. As of March 2024, the state had registered 167,153 patients who were legally allowed to use medical cannabis.

Ohio’s medical cannabis program covers 26 eligible conditions, including post-traumatic stress disorder (“PTSD”) and chronic and intractable or severe pain, among others. The program permits cannabis to be sold as edibles, tinctures, oils, plant material and patches in 124 dispensaries across Ohio.

Now, a recently conducted survey has discovered that the majority of medical marijuana patients have observed a reduction in their use of prescription painkillers. Almost 3,500 people took part in the survey, with some being recruited through a newsletter distributed to patients and caregivers at Ohio Medical Marijuana Control program and others though Ohio State University’s Drug Enforcement and Policy Center network.

The survey focused on two issues: whether participants had reduced their use of other illicit substances after using cannabis and whether cannabis had decreased the need for prescription drugs.

The survey directed that all respondents record the extent to which they agreed with two statements reflecting those issues, with 77.5% agreeing that using cannabis had decreased their need for prescription medications. Another 26.7% agreed that cannabis use had decreased their need to use other illicit substances. The survey’s findings are consistent with those of other studies.

In their report, the researchers stated that their study had some limitations. Despite this, they still hold the opinion that cannabis-related research may become easier to carry out if cannabis is rescheduled as has been recommended by the U.S. Justice Department.

The researchers also recognized that the use of cannabis could have negative impacts on an individual’s health, noting that more studies were required to determine the drug’s safety and effectiveness compared to other therapies. This, they argued, could be moved along with marijuana’s rescheduling to Schedule 3 from 1 of the Controlled Substances Act, as recommended by the U.S. Health and Human Services department (HHS).

In its letter to the U.S. Drug Enforcement Administration (DEA), the Health and Human Services department states that cannabis has an accepted medical use in treatment in the United States and low potential for abuse as compared to other drugs under Schedule 1 or 2.

Interested individuals can access a preprint of the study report here. It should be noted that at the time of publishing, the study hadn’t been peer reviewed.

It is also worth noting that Ohio recently legalized adult-use marijuana via a ballot initiative, voter approved in 2023. As the market takes off, it could create opportunities for local companies offering services similar to those that enterprises such as Innovative Industrial Properties Inc. (NYSE: IIPR) offer in the markets in which they operate.

Innovative Industrial Properties Inc. (IIPR), closed Friday's trading session at $122.93, up 1.8138%, on 143,114 volume. The average volume for the last 3 months is 47.551M and the stock's 52-week low/high is $69.08/$124.00.

Intel Corp. (INTC)

FreeRealTime, The Street, InvestorPlace, Kiplinger Today, StockMarketWatch, Schaeffer's, StreetAuthority Daily, Zacks, The Online Investor, MarketClub Analysis, Investopedia, StreetInsider, Daily Trade Alert, Trades Of The Day, TopStockAnalysts, Money Morning, MarketBeat, CNBC Breaking News, Barchart, Early Bird, Dividend Opportunities, StocksEarning, PROFIT CONFIDENTIAL, Market Intelligence Center Alert, InvestorGuide, SmarTrend Newsletters, Louis Navellier, INO Market Report, The Motley Fool, Street Insider, TheStockAdvisors, Daily Profit, ProfitableTrading, Daily Wealth, Top Pros' Top Picks, INO.com Market Report, Uncommon Wisdom, Wyatt Investment Research, The Wealth Report, internetnews, TradingAuthority Daily, TheStockAdvisor, Trading Markets, Wealth Insider Alert, internet, Money Wealth Matters, Insider Wealth Alert, Investor Guide, Marketbeat.com, StrategicTechInvestor, SiliconValley, CustomerService, Money and Markets, The Best Newsletters, MarketWatch, The Street Report, Investors Alley, WStreet Market Commentary, Market FN, DrStockPick, StreetAlerts, GorillaTrades, Cabot Wealth, Wealth Daily, The Growth Stock Wire, IT News Daily, DividendStocks, Daily Dividends, InsiderTrades, Investor Update, Daily Markets, Investing Daily, Wall Street Daily, TradingMarkets, Trading Tips, Eagle Financial Publications, QualityStocks, Forbes, CRWEWallStreet, AllPennyStocks, CRWEFinance, ChartAdvisor, StockHotTips, Greenbackers, Stockhouse, Trade of the Week, Leeb's Market Forecast, TipRanks, Investment U, BestOtc, Trading Concepts, PennyOmega, Coattail Investor, CRWEPicks, PennyToBuck, Dynamic Wealth Report, FeedBlitz, InvestmentHouse, Market Authority, SmallCap Network, StockEarnings, Super Stock Investor, The Night Owl, Energy and Capital, SmallCapVoice, FeedTheBull, Market Intelligence Center, SwingTradeOnline, Darwin Investing Network, iStockAnalyst, Wall Street Elite, Taipan Daily, Investment House, FNNO Newsletters, Wealthpire Inc., OnTheMar, wyatt research newsletter, Trader Prep, Market Wrap Daily, The Dividend Guy, Jon Markman’s Pivotal Point, InvestorsObserver Team, Investing Signal, Investing Lab, Willy Wizard, The Stock Enthusiast, Inside Investing Daily, Quant Ratings Team, Penny Stock Buzz, 24/7 Trader, SmallCapNetwork, Stock Gumshoe, PennyStockOracle, The Daily Market Alert, InvestorIntel, Total Wealth, Bloomfield Investment Club, StockTwits, Wall Street Greek, Earnings360, Shah's Insights & Indictments, Wall Street Resources, INO Traders Blog, All Star Investor, Premium Stock Alerts, Stocks in the Spotlight, Short Term Wealth, Market Pulse, Hit and Run Candle Sticks, Jim Cramer, Equities.com, The Weekly Options Trader, Millennium-Traders, FlintFreeFinance, The Trading Report, Profitable Trader Authority and TheOptionSpecialist reported earlier on Intel Corp. (INTC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Estimates show that roughly 70% of energy generated around the globe is wasted. Experts believe that more efficient systems to generate power could be designed if researchers were able to forecast how heat passes through insulators and semiconductors. This is hard to do at the moment, however, because it is challenging to model the thermal properties of different materials.

The issue stems from subatomic particles that carry heat, known as phonons. A group of MIT researchers have designed a new framework based on machine-learning, which can forecast phonon dispersion relation about 1,000 times faster than other methods based on artificial intelligence (“AI”).

This technique may assist engineers in designing systems to generate energy that efficiently generate more power. It could also aid in the development of efficient microelectronics.

Mingda Li, an associate professor of engineering and nuclear science, states that obtaining the properties of phonons is challenging, either experimentally or computationally. The researchers’ approach calculates the phonon dispersion relation for a material, with the researchers using graph neural networks to convert the atomic structure of a material into a graph made up of multiple nodes linked by edges.

While graph neural networks can help calculate quantities such as electrical polarization or magnetization, they aren’t flexible in a way that allows them to forecast phonon dispersion relation. To acquire flexibility, the researchers came up with a virtual node graph neural network that allows the neural network’s output to vary. This allowed them to estimate phonon dispersion relations, with the researchers observing that the virtual node graph neural network provided more accuracy when forecasting the heat capacity of a material.

The researchers believe that this efficiency may enable the creation of a bigger space when looking for materials with specific thermal properties such as superconductivity, or thermal storage. Additionally, they posit that their technique could also be utilized in forecasting challenging magnetic and optical properties.

For the future, the scientists are focused on refining this method so virtual nodes can record any small change that may impact the structure of phonons with additional sensitivity.

Li, the senior author of this study, was joined in doing this research by MIT’s Thomas Siebel; professor of electrical engineering and computer science Tommi Jaakkola; chemistry grad student Ryotaro Okabe; and MIT electrical engineering and computer science graduate student Abhijatmedhi Chotrattanapituk, among others.

Their findings were reported in “Nature Computational Science.”

This study was supported by the Oak Ridge National Laboratory, the Harvard Quantum Initiative, a Sow-Hsin Chen Fellowship, a Mathworks Fellowship, the National Science Foundation and the U.S. Department of Energy.

It is anticipated that during the coming years, tech companies such as Intel Corp. (NASDAQ: INTC) are likely to bring many innovative AI solutions onto the market that could revolutionize the different industries in which they are used.

Intel Corp. (INTC), closed Friday's trading session at $31.35, up 0.8038585%, on 38,352,543 volume. The average volume for the last 3 months is 50.71M and the stock's 52-week low/high is $29.73/$51.28.

NIO Inc. (NIO)

Green Car Stocks, InvestorPlace, Schaeffer's, MarketClub Analysis, The Street, StocksEarning, MarketBeat, StockEarnings, QualityStocks, Daily Trade Alert, Kiplinger Today, Trades Of The Day, The Online Investor, Early Bird, INO Market Report, Zacks, StreetInsider, StockMarketWatch, FreeRealTime, BUYINS.NET, Cabot Wealth, GreenCarStocks, TipRanks, Money Wealth Matters, Wealth Insider Alert, CNBC Breaking News, The Wealth Report, Earnings360, AllPennyStocks, InvestorsUnderground, Louis Navellier, Investopedia, TradersPro, Daily Wealth, wyatt research newsletter, BillionDollarClub, InvestorsObserver Team, Energy and Capital, CRWEWallStreet, DividendStocks, Green Energy Stocks, InvestorIntel, Wealth Daily, Investors Underground, Jim Cramer, MarketClub, TopPennyStockMovers, Top Pros’ Top Picks, Smartmoneytrading, Stock Market Watch, Top Pros' Top Picks, The Night Owl, Tim Bohen and Investors Alley reported earlier on NIO Inc. (NIO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Over the past few days, NIO Inc. (NYSE: NIO) has been making headlines with its stock price rally, sparking great interest among investors and analysts alike. As of the latest update, its stock price is $4.65, reflecting an 8.42% decline over the past week.

This price fluctuation has prompted both excitement and caution among investors. However, from a wider perspective, the stock has surged by 17.37% over the past three months. The fluctuation stresses the dynamic nature of the Chinese electric vehicle (EV) manufacturer’s position in the market and investor sentiment toward electric vehicle (EV) stocks in general.

With a market capitalization of $9.7 billion, NIO is in the mid tier of EVs and is known for its innovation and premium offerings. Despite the recent gains, the GF Value stands at $13.8, signifying that while the company’s stock has shown strength in the short-term, its financial performance remains a significant source of concern.

NIO’s operating margin is at a worrying -41.91%, indicating significant operational losses. Its Return on Equity (ROE) and Return on Assets (ROA) are also deeply negative, at -111.57% and -21.41%, respectively. These figures show the substantial challenge the EV company must overcome to turn its technological prowess into consistent profitability. Financial analysts are anticipating continued losses for the EV maker through 2025. Negative earnings per share estimates predict that the company will not be making profits during this period.

On the growth front, NIO has demonstrated robust revenue growth, a positive indication of the company’s financial performance. It has a high growth rank of 10/10, with robust revenue growth rates. A 10/10 growth rank is a key measurement used to assess a company’s growth rate compared to others in the same industry.

Additionally, NIO’s revenue per share grew at an average annual rate of 29.70% over the past three years. Its 5-Year Revenue Growth Rate per Share is 27.30%, meaning that its revenue per share grew at an average annual rate of 27.30% over the past five years.

Industry analysts are predicting a continued growth trajectory with an estimated Total Revenue Growth Rate of 21.35% over the next three to five years. However, its earnings per share (EPS) growth has been uneven, with a negative three-year rate of -28.00% but a promising five-year growth rate of 24.30%.

Despite the financial metrics, NIO operates in a competitive electric vehicle market with rivals such as XPeng, VinFast and Rivian. The company continues to capture the attention of high-profile investors such as Baillie Gifford, Steven Cohen and Ray Dalio, who hold significant stakes in the company. The support and backing from notable investors can often sway market sentiment, encouraging others to consider NIO a viable investment option despite its current financial hurdles.

NIO Inc. (NIO), closed Friday's trading session at $4.43, up 3.7471%, on 32,103,355 volume. The average volume for the last 3 months is 80,595 and the stock's 52-week low/high is $3.61/$16.18.

Kandi Technologies Group Inc. (KNDI)

Green Car Stocks, QualityStocks, MarketClub Analysis, InvestorPlace, Schaeffer's, The Street, StockMarketWatch, Hit and Run Candle Sticks, StreetInsider, TraderPower, Alternative Energy, Jason Bond, Greenbackers, GreatStockPix, Wall Street Resources, MarketBeat, GreenCarStocks, TradersPro, China Stock Alerts, BUYINS.NET, Investing Futures, Marketbeat.com, Money Morning, Penny Stock Rumble, ProfitableTrading, SmarTrend Newsletters, StreetAuthority Daily, Trades Of The Day, TradingMarkets, The Wealth Report, TopStockAnalysts, FeedBlitz, Energy and Capital, Dynamic Wealth Report, DrStockPick, Money and Markets, CRWEWallStreet, INO.com Market Report, CRWEPicks, CRWEFinance, CoolPennyStocks, ChartAdvisor, Weekly Wizards, BullRally, BestOtc, Barchart, Daily Trade Alert, Stock Traders Chat, Profit Confidential, PennyTrader Publisher, PennyToBuck, PennyStockVille, PennyOmega, PennyInvest, Rick Saddler, SmallCapNetwork, Street Insider, SmallCapVoice, HotOTC, MadPennyStocks, StockEgg, InvestorsUnderground, Investors Alley, StockHotTips, InvestorGuide, Investor Ideas, StockRich and Willy Wizard reported earlier on Kandi Technologies Group Inc. (KNDI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ford Motors has announced that it is ditching its goal of fully electrifying its vehicle lineup in Europe by 2030. The American automaker had set the relatively ambitious goal of only selling electric cars on the European market by the end of the decade, but it is scaling back those plans in the wake of slower-than-expected EV uptake.

Model E electrification division chief operating officer Marin Gjaja says Ford will continue selling ICE cars as well as battery electric vehicles (BEVs) and hybrids. The recent slowdown in electric vehicle sales has forced most established automakers to rethink their electrification plans. With fewer customers opting to buy electric cars amid high purchase costs, high interest rates and rising living costs, carmakers such as Ford are revising their strategies, reducing their investments in electric cars and focusing on diverse product lines.

Gjaja notes that high electric vehicle-battery costs coupled with the uncertainty around EV policies and subsidy programs have made many customers reconsider going electric. Electric vehicles still cost more than their gas-powered counterparts, and a significant portion of the market relies on government subsidies to reduce the costs. Customers are less likely to purchase electric cars if they are uncertain they will receive this financial support.

Consequently, Gjaja says Ford will continue selling ICE cars and focus on developing hybrid powertrains. He adds that Ford can’t focus all its attention on a single product line until the market decides it is all in. Continuing to work toward full electrification in the European market by 2030 wouldn’t be a good business choice for both Ford and its customer base, he says.

Despite scaling back its electrification goals, Gjaja notes that electrifying its entire vehicle lineup is still one of Ford’s core long-term goals. If the company can figure out a balance between energy density and EV battery costs, he observes, Ford could ultimately end up with a “highly electrified fleet” of vehicles. Electrification has been a core tenet of the Biden administration, and the federal government has invested billions of dollars into building America’s EV market and developing a robust public charging network.

As transportation is responsible for roughly one-third of America’s greenhouse-gas emissions, electrifying the segment would bring the United States one step closer to curbing its emissions and mitigating climate change. Carmakers will most likely be subject to stricter emission standards over the next few decades to speed up total electrification. In the meantime, however, Ford will focus on gas-powered cars, hybrids and EVs to remain competitive and better serve their customers’ needs.

These legacy automakers are also feeling the pressure from Chinese EV makers such as Kandi Technologies Group Inc. (NASDAQ: KNDI). The threat posed by this competition is giving EV makers in the west plenty to think about if they are to remain competitive in the decades to come.

Kandi Technologies Group Inc. (KNDI), closed Friday's trading session at $1.915, up 2.4064%, on 36,043 volume. The average volume for the last 3 months is 5.66M and the stock's 52-week low/high is $1.76/$3.74.

Match Group Inc. (MTCH)

InvestorPlace, Schaeffer's, Marketbeat, MarketClub Analysis, StocksEarning, The Street, Kiplinger Today, Daily Trade Alert, StreetInsider, Trades Of The Day, StockEarnings, Daily Wealth, Trading Tips, Money Wealth Matters, Zacks, Stockpalooza, Investopedia, Market Intelligence Center Alert, Wealth Insider Alert, Stock Stars, The Online Investor, QualityStocks, Trading Concepts, Marketbeat.com, Top Pros' Top Picks, Stock Rich, StockHotTips, Penny Invest, HotOTC, StockMarketWatch, StreetAuthority Daily, OTC Advisors, OTCReporter, Louis Navellier, CoolPennyStocks, StockEgg, CNBC Breaking News, TopStockAnalysts, SmallCapVoice, Barchart, BUYINS.NET, Investment U, InvestmentHouse, GorillaTrades, Wealth Daily, Epic Stock Picks, Energy and Capital, PennyOmega, Cabot Wealth, InsiderTrades, Titan Stocks, StockPickss, Topgun stockpicks, The Stock Dork, Standout Stocks, Monster Stox, DividendStocks, Early Bird, wyatt research newsletter, FreeRealTime, XplosiveStocks, GusherStocks, Daily Profit, BloomMoney, OTCPicks, The Trading Report, TipRanks, Stock Traders Chat, Stock Marketing Inc., Stock Market Watch, SpeculatingStocks, Wall Street Daily, PennyStockRumors.net, Investiv, The Motley Fool, Profit Confidential, Uncommon Wisdom, InvestorsObserver Team, Wise Alerts, WStreet Market Commentary, Investment House and Smart Investing Today reported earlier on Match Group Inc. (MTCH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Match Group (NASDAQ: MTCH), a leading company in the online dating industry, operates well-known platforms such as Tinder, Hinge, and OkCupid. The company has recently been in the spotlight due to a significant investment by the activist hedge fund Starboard Value, which has acquired approximately 6.6% of Match Group, making it the third-largest shareholder.

Starboard Value’s involvement is not just a passive investment. In a detailed letter to Match Group’s leadership, Jeffrey Smith, Starboard Value’s Managing Member, outlined several recommendations aimed at boosting the company’s financial performance. Among these suggestions was the need for Match to improve its profit margins, with a specific target to elevate its adjusted operating margins above 40%. This is a significant point of focus, considering Match Group’s revenue has grown from around $2 billion in 2019 to an expected $3.6 billion this year, yet its adjusted operating margins have declined during the same period.

Additionally, Smith proposed that Match Group should ramp up its stock buyback efforts. This strategy involves the company repurchasing its own shares, which can benefit shareholders by increasing the value of remaining shares and reducing the overall number of shares outstanding. Such a move is seen as an effective use of cash that could enhance shareholder value. Furthermore, Smith mentioned that if Match Group is unable or unwilling to implement these suggestions, the company could also consider going private, with Starboard expressing its support for such a move.

The news of Starboard Value’s investment and its push for strategic changes has had a positive impact on Match Group’s stock, which saw an increase of more than 9% to $35.00 by 7:45 a.m. ET Tuesday. This uptick is particularly noteworthy, considering the stock had experienced a loss in value of approximately 12% so far this year through Monday. The current trading price of $32.88, with fluctuations between $32.86 and $33.35 during the trading day, reflects the market’s ongoing assessment of Match Group’s value and potential. With a market capitalization of around $8.74 billion and a trading volume of 656,094 shares, Match Group remains a significant player in the online dating market, now under the watchful eye of Starboard Value and its proposed strategic initiatives.

To view the company’s Q1 earnings release, visit https://ibn.fm/EZJ82

About Match Group

Match Group, through its portfolio companies, is a leading provider of digital technologies designed to help people make meaningful connections. Its global portfolio of brands includes Tinder(R), Hinge(R), Match(R), Meetic(R), OkCupid(R), Pairs(R), PlentyOfFish(R), Azar(R), BLK(R), and more, each built to increase its users’ likelihood of connecting with others. Through the company’s trusted brands, it provides tailored services to meet the varying preferences of its users. Match Group’s services are available in over 40 languages to users all over the world.

Match Group Inc. (MTCH), closed Friday's trading session at $33.25, even for the day, on 3,176,664 volume. The average volume for the last 3 months is 1.799M and the stock's 52-week low/high is $27.655/$49.24.

Cronos Group Inc. (CRON)

InvestorPlace, Schaeffer's, Kiplinger Today, MarketClub Analysis, StocksEarning, The Street, QualityStocks, MarketBeat, Daily Trade Alert, Trades Of The Day, Wealth Insider Alert, The Online Investor, StockEarnings, Market Intelligence Center Alert, StockMarketWatch, StreetInsider, BUYINS.NET, The Wealth Report, Zacks, Top Pros' Top Picks, Stock Up Featured, Investopedia, Cabot Wealth, InvestmentHouse, Daily Profit, CannabisNewsWire, Jim Cramer, Early Bird, InsiderTrades, The Rich Investor, TheTradingReport, Wall Street Window, InvestorsUnderground, Money Morning, VectorVest, 24/7 Trader, Small Cap Firm, Stock Gumshoe and InvestorsObserver Team reported earlier on Cronos Group Inc. (CRON), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A recent study highlights that more than 20% of patients visiting orthopedic surgeons for chronic musculoskeletal (MSK) pain have turned to marijuana for relief. Among these individuals, nearly two-thirds found marijuana to be somewhat effective, and more than 90% reported at least slight effectiveness.

The study indicates that 57% of patients considered cannabis more effective than other pain medications, with 40% reducing their use of other analgesics since starting cannabis. However, only 26% had cannabis recommended by a physician for their MSK pain.

The most frequently used cannabinoid among the patients was CBD, with 39% favoring it. Another 20% preferred a mix of various cannabinoids, while 23% were unsure about the composition of their marijuana. Interestingly, among nonusers, about 65% expressed interest in trying cannabis for pain management but faced obstacles such as lack of access, knowledge and evidence.

The study, featured in the “Cannabis Research Journal,” did not aim to definitively prove the effectiveness of cannabis in managing MSK pain. Instead, it focused on usage patterns, self-reported effectiveness and barriers to use among nonusers. The cohort consisted of 629 adult patients (18 years of age and older) with chronic MSK pain who visited Toronto Western Hospital for the first time to see an orthopedic surgeon.

According to the report, 72% of those who had previously used marijuana as a pain reliever still did so as part of their treatment plan. The preferred methods of consumption were oils (57%), smoking (36%) and vaporizing (32%). Common side effects reported were dry mouth (43%), lack of motivation (15%) and fatigue (23%), while 39% experienced no side effects. Additionally, many users found cannabis effective for other symptoms, such as headaches (18%), sleep disturbances (44%) and anxiety (26%), although 43% reported no relief for these symptoms.

Patients obtained the products from various sources, including compassion clubs or dispensaries (43%), licensed providers (34%), and relatives and friends (33%). Despite the relief reported, the study found that users often experienced more pain and a broader range of other health issues. However, the researchers did not attribute these conditions to marijuana use, suggesting that those with more severe conditions might seek marijuana as an alternative or additional relief.

In comparison to nonusers, the study found that marijuana users frequently had more comorbid conditions, such as greater rates of depression, more painful body parts and more frequent trips to pain specialists. This implies that the use of cannabis may be a reaction to more intense pain and discontentment with conventional therapies. Additionally, those who used cannabis also frequently took a broader variety of drugs, including opioids, muscle relaxants and antidepressants. This could mean that people looked to cannabis as a backup therapy when other therapies weren’t working.

Chronic pain syndrome was found to be one of the most reliable indicators of cannabis usage, suggesting that individuals with chronic MSK pain frequently feel unsatisfied with traditional therapies and turn to alternative pain-management techniques. But the largest predictor, which more than tenfold increased the risk of utilizing cannabis for pain management, was prior recreational marijuana use.

The authors called for more double-blind, placebo-controlled trials to better understand the effectiveness of cannabis for pain management, acknowledging the potential for a placebo effect.

These views expressed by marijuana users could give medical cannabis companies such as Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) some additional pointers on how to better position their products to serve the needs of these categories of patients.

Cronos Group Inc. (CRON), closed Friday's trading session at $2.42, even for the day, on 401,801 volume. The average volume for the last 3 months is 191 and the stock's 52-week low/high is $1.64/$3.14.

Glidelogic (GDLG)

We reported earlier on Glidelogic (GDLG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Glidelogic (OTC: GDLG), a diversified software development company specializing in artificial intelligence, fintech, and blockchain technology development and consulting, has announced a groundbreaking solution for copyright protection of artificial intelligence (“AI”)-generated content. According to the announcement, the offering combines Glidelogic's patented technology with Propaganda GEM's industry resources, creating a copyright management system designed for digital content creators and users. The technology utilizes a large model to encode copyrighted content with user information, generating customized NFTs and ensuring the uniqueness of each work while also providing a clear chain of copyright ownership and ensuring content is legal and compliant. Propaganda GEM is a leading Hollywood entertainment marketing and IP licensing company. “This innovative copyright protection solution links and balances the interests of IP holders, technology providers and AI creators, establishing a feasible cooperation framework,” said Glidelogic CEO Yitian (Fred) Xue in the press release. “By offering verifiable AI creation services, we not only protect the rights of content creators but also provide users with a more trustworthy and secure digital content experience. This technology is groundbreaking and will fundamentally change the digital content ecosystem, bringing unprecedented trust and security to IP holders, content creators, and users.”

To view the full press release, visit https://ibn.fm/czvy4

About Glidelogic Corp.

Glidelogic was founded in December 2020 and is headquartered in Culver City, California. The company is committed to developing artificial intelligence (“AI”)-based software, fintech solutions and blockchain technology, as well as providing related consulting services. The company’s mission is to leverage leading AI technology to offer forward-looking services to commercial clients, thereby enhancing productivity. For more information, visit the company’s website at www.GlideLogic.ai.

Glidelogic (GDLG), closed Friday's trading session at $0.25, even for the day. The average volume for the last 3 months is 230,514 and the stock's 52-week low/high is $0.20/$0.35.

BitFuFu Inc. (FUFU)

QualityStocks and 360 Wall Street reported earlier on BitFuFu Inc. (FUFU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

KPMG, one of the top four accounting companies globally, has teamed up with Cryptio, a cryptocurrency accounting software provider, to support U.S.-based crypto companies in adhering to Generally Accepted Accounting Principles (GAAP). This strategic cooperation seeks to improve the precision and dependability of cryptocurrency companies’ accounting for their assets through the implementation of efficient controls.

Brian Consolvo, KPMG principal for technology risk, stressed the importance of improving digital asset accounting procedures and complying with U.S. regulatory requirements. He noted, “KPMG recognizes the value of accurate reporting and accounting, the risks associated with crypto assets, as well as the need for robust internal controls.”

The collaboration will enable crypto institutions and businesses to fulfill their GAAP reporting and accounting requirements using Cryptio’s software.

Antoine Scalia, CEO and founder of Cryptio, noted that this alliance is essential to the long-term viability of the cryptocurrency market. “Our partnership with KPMG gives businesses and organizations the assurance they need to handle accounting procedures, audits and regulatory reporting,” said Scalia. “By working together, we are creating a standard for regulated organizations implementing digital assets.”

Kunal Bhasin, who leads the digital assets practice at KPMG Canada, noted that increasing debt and inflation are the main reasons pushing institutional investors toward cryptocurrencies.

A recent survey by KPMG found that in 2023, almost 40% of institutional investors had interacted with cryptocurrency assets, up from 31% in 2021. Out of the 65 participants in the poll, 31 were institutional investors that oversee assets valued at more than $500 million, and the remaining 34 were financial services companies.

Additionally, the poll showed that, compared to two years ago, one-fifth of these institutional investors now held 10% or more of their portfolio in cryptocurrency assets. The market’s maturing, and enhanced custody infrastructure, are two important drivers of the rising customer demand for services related to crypto assets.

Crypto financial reporting requirements are being advanced globally. For instance, in Hong Kong, a new software called FinTax is assisting individuals in filing their taxes amid the rise of cryptos. The region has also approved spot Ethereum and Bitcoin ETFs, demonstrating the global efforts to regulate the crypto sector.

In the U.S., the Securities Exchange Commission has made it clear that brokerage houses and banks are not compelled to disclose their clients’ crypto holdings in their registrations. The goal of this strategy is to guarantee that financial institutions can handle the risks involved efficiently.

It remains to be seen whether the solution offered by Cryptio and KPMG is superior and more cost-effective in comparison to the in-house mechanisms that industry actors such as BitFuFu Inc. (NASDAQ: FUFU) had put together to address their needs.

BitFuFu Inc. (FUFU), closed Friday's trading session at $4.75, off by 5.2841%, on 138,363 volume. The average volume for the last 3 months is 39,549 and the stock's 52-week low/high is $2.32/$18.32.

The QualityStocks Company Corner

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene's mission is to transform the treatment of neurodegenerative diseases with a new class of drugs, potentially impacting the lives of millions

The company's uniquely structured gold nanocrystals have the remarkable ability to convert critical energetic metabolites in living cells for the production of ATP, the essential energy currency for cellular functions, offering disease combatting capabilities

Clene is currently preparing for Phase 3 clinical trials of CNM-Au8for ALS and MS, following successful early studies

Xtalks Life Science Podcast recently featured Karen S. Ho, PhD, Vice President of Translational Medicine for Clene (NASDAQ: CLNN), a late-stage biopharmaceutical company focused on protecting mitochondrial health and neuronal function to treat neurodegenerative diseases. In the episode, host Ayesha Rashid, PhD, discussed Clene's innovative gold nanocrystal technology and how Dr. Ho is leading the company's development in diseases like ALS (Amyotrophic Lateral Sclerosis), MS (Multiple Sclerosis), and PD (Parkinson's Disease).

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Friday's trading session at $4.49, up 0.6726457%, on 22,470 volume. The average volume for the last 3 months is 1.083M and the stock's 52-week low/high is $4.23/$15.80.

Recent News

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)

The QualityStocks Daily Newsletter would like to spotlight Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI).

New research has highlighted the increased risk of illnesses spreading to humans from animals. The report by researchers from New York University and Harvard Law School examined common interactions between humans and animals in 15 countries, including the United States. The researchers discovered numerous examples where viruses could spread to humans, explaining that while zoonotic illnesses, including monkeypox and smallpox, had always existed, their prevalence was growing as interactions between animals and humans increased with urban expansion, climate shifts and international travel. In addition, the researchers proposed that known risks be decreased via methods such as pasteurization of milk and its products, avoiding kissing animals, washing hands after touching animals and processing animals carefully. This, they explained, was also important in protecting the animals because they can also contract some diseases from humans. For instance, many pets contracted the coronavirus from their human families. Mercy for Animals, a global nonprofit animal protection organization, supports this approach. As the alarm is sounded regarding the need to take steps to prevent the spread of diseases from animals to humans, some entities such as Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) are already taking the proactive step of developing immunotherapies against several infectious diseases so that any outbreak that occurs is limited in its impact.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, Scinai is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. Scinai is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, Scinai has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, Scinai signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. Scinai anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of Scinai’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

Scinai has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, Scinai will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. Scinai anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

CDMO Services

While NanoAb pipeline development is Scinai’s core focus, the company also offers its cGMP manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for contract development and manufacturing organization (CDMO) services. This offering is designed to keep the Scinai team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s NanoAb pipeline development.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future Scinai drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is Scinai’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at Scinai. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at Scinai. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining Scinai, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at Scinai. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to Scinai through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), closed Friday's trading session at $4.36, up 15.6499%, on 193,624 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $15.80/$.

Recent News

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF)

The QualityStocks Daily Newsletter would like to spotlight Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF).

Last week, JLL and IBM rolled out a sustainability system available to clients around the globe. IBM is a multinational tech company based in the United States while JLL is an international real estate services company based in the United Kingdom. The new solution, called Sustainability Program Management, is powered by EnviziESG suite and offered by the sustainability services arm of JLL. The program offers sustainability services such as decarbonization strategies to be employed within commercial real estate operations. It is focused on addressing issues commercial real estate organizations face, including collecting or managing data on real estate portfolios for public reporting and decision-making. JLL global head of sustainability services, Guy Grainger, noted that the company's clients continued to rely on it to deliver strategies to decarbonize their portfolios as ESG reporting requirements became compulsory. Grainger revealed that Envizi was chosen as the preferred solution because it allows the company's team of sustainability experts to offer more reliable data management and reporting. As more enterprises such as IBM and JLL come up with innovative solutions to ease ESG reporting for various industries and verticals, extractive entities such as Reflex Advanced Materials Corp (CSE: RFLX) (OTCQB: RFLXF) could also soon gain a provider that understands their unique needs and has something to streamline the collection and reporting of their data on ESG.

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) is a strategic minerals company focused on locating and developing economic properties in the strategic metals and advanced materials space. The company aims to improve domestic specialty mineral infrastructure efficiencies to meet surging national demand from North American manufacturers, effectively positioning itself as one of the only North American suppliers of high purity natural graphite for hi-tech applications.

Reflex Advanced Materials is based in Vancouver, British Columbia. Its project portfolio includes the Ruby Graphite Deposit in Montana and the ZigZag Lithium Property in Ontario.

Projects

Ruby Graphite Project

Located in a mining-friendly jurisdiction in southwest Montana, the Ruby Graphite Deposit is a low cost, rapid re-entry opportunity that produced roughly 2,400 tons of graphite from 1902 to 1948. Reflex Advanced Materials holds mining rights for 755 hectares at the Ruby Graphite Project, with 96 federal lode mining claims. Recent samples assay at 95.8% to 98.4% total carbon.

The site is notable as the only combined U.S. graphite flake and vein graphite source. Vein graphite is ideal for energy storage applications, because it requires fewer steps to achieve purity than synthetic alternatives and is therefore far less environmentally damaging. This is expected to play a key role in the project’s development as demand for electric vehicles continues to surge.

In March 2023, the company announced its submittal of permit applications to the Bureau of Land Management in respect of its exploration of the Ruby Graphite Project. Its initial drill program, expected to take place in the summer of 2023, includes plans for 3,500 total meters of drilling, cored to an average depth of 130 meters. The targets for this drill program have been identified using historical data from original mine operations and data gathered for the initial 43-101 technical report on the project, dated January 31, 2023.

ZigZag Lithium Property

Located in the Thunder Bay Mining Division of Ontario, the ZigZag Lithium Property consists of eight mining claims spanning roughly 2,710 hectares. Mineralization at the property, most notably lithium, is based in pegmatite dikes and concentrated in spodumene crystals, which are consistent throughout the entire unit.

Spodumene is readily observable in outcrops and in drill cores, with crystal sizes ranging from 3-15cm, on average.

Reflex Advanced Materials and American Energy Technologies Company Metallurgical Partnership

Reflex Advanced Materials has entered into a material processing agreement with American Energy Technologies Co., which is based in Arlington Heights, Illinois, to conduct metallurgical testwork with the goal of creating a technical support data package for Reflex’s target customer base, U.S. Federal agencies and qualification programs with hi-tech customers in the battery and battery storage business.

The resulting coated, spherionized, purified graphite (CSPG) material that is expected to be created from the aforementioned tests will be used to provide potential customers of CSPG with samples so that they can begin the material qualification process.

Market Opportunity

Graphite is an ideal battery anode and has dominated the market since the proliferation of lithium-ion batteries. Despite this demand, there is currently no significant production of lithium-ion battery anode material in North America.

Instead, most graphite sold in North America today is sourced from Chinese producers. U.S. President Joe Biden highlighted this sourcing disparity in a 2022 address:

“The United Stated depends on unreliable foreign sources for many of the strategic and critical materials necessary for the clean energy transition – such as lithium, nickel, cobalt, graphite and manganese for large-capacity batteries,” he said. “Demand for such materials is projected to increase exponentially as the world transitions to a clean energy economy.”

The U.S. Department of Energy is in the process of awarding $2.8 billion to expand domestic manufacturing of batteries for electric vehicles and combat this foreign dependency. Reflex Advanced Materials has identified its Ruby Graphite Project as a prime candidate for U.S.-sponsored initiatives due to the rarity and scarcity of natural graphite deposits in the country.

Processing graphite domestically in the U.S. is expected to provide Reflex Advanced Materials a competitive advantage as manufacturers begin to seek out American supply in the face of increased diplomatic tension. This is critical, as a rise in anode demand is expected to fuel a shortage of 8 million tonnes of graphite by 2040. World Bank Group projects 494% growth in total graphite demand by 2050.

Leadership Team

Paul Gorman is the CEO and a Director of Reflex Advanced Materials. He brings to the company over 25 years of experience in junior mining finance, public listings, viability assessment and operational rationalization. For 18 years, Mr. Gorman served as president and managing partner of Riverbank Capital, where he played an instrumental role in raising more than $85 million for small-cap companies. In 2008, he funded Industrial Minerals Inc. (later Northern Graphite) and served in an advisory role for four other graphite companies, contributing significantly to the revitalization of the junior graphite space in North America. Mr. Gorman founded Mega Graphite Inc. in 2009 and has served as chief executive for three other companies.

Tasheel Jeerh, CPA, is the company’s CFO. He is a finance and accounting professional with over a decade of experience spanning both public and private sectors. Prior to joining Reflex Advanced Materials, Mr. Jeerh played a pivotal role in the growth of a private upstream oil and gas firm, dealing with over $2 billion in M&A activity and $1 billion in financing activities. He gained his designation at PricewaterhouseCoopers, where he worked as a manager in the assurance practice.

Greg Bell is Project Manager for Reflex Advanced Materials. He is a multi-disciplined engineering management professional with more than 40 years of experience in the natural resources sector. Mr. Bell has successfully built and managed several start-up operations in various capacities. He has been active in graphite and lithium exploration for the past seven years.

Christopher W. Hill leads the company’s Corporate Development initiatives. He is an investor and entrepreneur with over a decade of experience in the capital markets. Mr. Hill began his career as an investment advisor and then began to consult and advise private companies on their paths to becoming publicly traded. He specializes in corporate development and strategic financing utilizing his large network in the capital markets.

Reflex Advanced Materials Corp. (RFLXF), closed Friday's trading session at $0.04045, up 28.4127%, on 16,118 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.03/$0.35.

Recent News

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF)

The QualityStocks Daily Newsletter would like to spotlight Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF).

Earlier this week, the price of copper fell to its lowest in more than three months. The significant drop in price was driven by demand concerns after China failed to issue fresh stimulus measures despite the struggling economy.

Daniel Ghali, a senior commodity strategist at TDS, notes that the continued rise in copper exports from China supports TDS's view of a weakness in domestic demand. He noted that the decline in demand expectations for the commodity suggest a rise in downside convexity. It is expected that policymakers will announce economic policies to promote domestic demand at the end of the month during the Politburo meeting. In other news, China saw its imports of coal, soybeans and iron ore increase in June while imports of rare earths and crude oil dropped. One rare earths analyst posited that the drop in exports was expected after overseas buyers increased procurement for the previous quarter. Currently, China is the largest importer of crude oil as well as the biggest buyer of soybeans, iron ore and coal. The broader outlook for copper is generally bullish, so entities such as Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) are unlikely to be rattled by these short-term fluctuations in the market for this metal.

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) is a mineral exploration company engaged in advancing precious and base metal deposits in the state of Arizona. Its flagship copper-gold-zinc-silver asset is the Kay Mine Project, located in Yavapai County. The company also owns Sugarloaf Peak gold project in La Paz County.

The company in October 2022 received permit approval from the Bureau of Land Management (BLM) for two new drill pads, located approximately 1,200 meters west of the Kay Mine Deposit. These new pads will allow for testing of the company’s Western Target, while also allowing for drilling of additional coincident anomalies located between the Central and Western Targets. Construction of the drill road for the Central Target (located 500 meters west of the Kay Mine Deposit) is currently underway, with drilling expected to begin in November 2022. Road construction for the Western Target will begin upon confirmation of BLM acceptance of the company’s posted bond, with drilling expected to commence in Q1 2023.

The company is fully funded, with $60 million in cash as of June 30, 2022, to complete the remaining 18,000 meters planned for the Phase 2 program at Kay, as well as an additional 76,000 meters in the Phase 3 program (budgeted at $27 million), which will be used to test the numerous parallel targets heading west of the Kay Deposit, as well as the northern and southern extensions of the Kay Deposit.

Arizona Metals Corp. is based in Toronto, Canada.

Projects

Arizona Metals Corp. owns 100% of the Kay Mine property in Yavapai County, which is located on a combination of patented and BLM claims totaling 1,300 acres that are not subject to any royalties. An historic estimate by Exxon Minerals in 1982 reported a “proven and probable reserve of 6.4 million short tons at a grade of 2.2% copper, 2.8 grams per ton gold, 3.03% zinc, and 55 grams per ton silver.” The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported by Exxon, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a “qualified person” (as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects) before the historic estimate can be verified and upgraded to be a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

The company also owns 100% of the Sugarloaf Peak Property in La Paz County, which is located on 4,400 acres of BLM claims. Sugarloaf is a heap-leach, open-pit target and has a historic estimate of “100 million tons containing 1.5 million ounces (of) gold” at a grade of 0.5 grams per ton. The historic estimate at the Sugarloaf Peak Property was reported by Westworld Resources in 1983. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a qualified person before the historic estimate can be verified and upgraded to a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

Market Opportunity

The World Gold Council, an industry association representing gold producers with hundreds of mining operations in nearly 50 countries around the world, reports that global demand for gold during the first six months of 2022 was 2,189 tons, a 12% increase in demand over the same period in 2021. Demand came primarily from gold bar and coin investors, jewelry consumers, central bank purchases to bolster currency reserves and technology manufacturing.

The average price per ounce for the period was $1,871, marking a 1% year-over-year increase. The council reported gold mine production for the period was up 3% over 2021 at 1,764 tons. For the remainder of 2022 and into 2023, the council projects flat gold demand with possible slight increases in gold mine production. The council notes that unpredictable geopolitical factors, the Ukraine war for example, and likelihood of global economic slowdown could have significant near-term impact on gold demand and prices.

Management Team

Marc Pais is President and CEO of Arizona Metals. He previously founded and served as President of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. He has seven years of experience as a Mining Analyst, with a focus on precious metals development companies. He holds a B.Sc. in Geological Engineering (Mineral Exploration) from Queen’s University in Canada.

David Smith is the Vice President, Exploration of Arizona Metals. He has 30 years of global precious metals exploration experience, including codiscovery of the Solidaridad/La Sabila deposit in Mexico with deposits estimated at 1 million ounces of gold. His core areas of expertise are managing mineral projects from acquisition to exploration, resource modeling and mineral project development. He holds an M.Sc. from the University of Oregon and an MBA from Pinchot University/Presidio Graduate School.

Paul Reid is the Executive Chairman of Arizona Metals. He previously founded and served as Executive Chairman of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. Paul has extensive experience as an Investment Banking professional, involved in raising capital, go-public transactions, and advisory services.

Arizona Metals Corp. (OTCQX: AZMCF), closed Friday's trading session at $1.37, off by 1.2257%, on 103,540 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.21/$2.50.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

Michigan has received a federal grant worth millions of dollars to fund utility-scale, clean-energy projects. The $129 million grant was announced by the U.S. Environmental Protection Agency ("EPA") to help advance Michigan's efforts to cut greenhouse gas emissions. According to EPA Midwest regional administrator Debra Shore, the grant will be used to provide assistance and incentives to local as well as tribal governments to speed up clean-energy projects. This will in turn accelerate renewable -energy adoption at scale and put Michigan on track to achieving its goal of using 60% green energy by 2030, Shore said. An EPA release from Congressman Dan Kildee noted the federal grant funding would help Michigan communities access the resources they need to return manufacturing jobs to the state and simultaneously preserve the environment. He said funding "critical investments" will be the key to cutting air pollution, advancing environmental justice, addressing the increasingly dire climate crisis and speeding up America's transition to renewables. With such funding, states could explore various green-energy solutions, including options being innovated by companies such as FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF) so that as many alternatives as possible can be used to meet the energy needs of residents.

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (https://ibn.fm/1OfOB).

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Friday's trading session at $0.034, off by 2.8571%, on 119,500 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.03/$0.07.

Recent News

Wheaton Precious Metals Corp. (TSX: WPM) (NYSE: WPM)

The QualityStocks Daily Newsletter would like to spotlight Wheaton Precious Metals Corp. (TSX: WPM) (NYSE: WPM).

Wheaton Precious Metals Corp. (TSX: WPM) (NYSE: WPM) is one of the largest precious metals streaming companies in the world. It generates revenue primarily from the sale of precious metals and cobalt while offering investors cost predictability, direct leverage to increasing precious metals prices and a high-quality asset base.

Wheaton seeks to be the world’s premier precious metals investment vehicle, delivering value through streaming to all stakeholders. The company has entered into agreements to purchase all or a portion of the precious metals or cobalt production from high quality mines for an upfront payment and an additional payment upon delivery of the metal. By crystallizing value for precious metals yet to be produced, Wheaton works with its partners to unlock and create value.

Wheaton currently has streaming agreements for 18 operating mines and 27 development stage projects. The company’s production profile is driven by a portfolio of low cost, long-life assets, including a gold stream on Vale’s Salobo mine and a silver stream on Newmont’s Penasquito mine.

With its portfolio of long-life, low-cost assets, Wheaton’s business model offers investors exposure to commodity prices and exploration upside with a much lower risk profile than a traditional mining company. Wheaton delivers among the highest cash operating margins in the mining industry, allowing it to pay a competitive dividend and continue to grow through accretive acquisitions. As a result, Wheaton has consistently outperformed gold and silver, as well as other mining investments.

The company is headquartered in Vancouver, British Columbia. Wheaton is committed to strong ESG practices and giving back to the communities in which its mining partners operate.

Business Model

The company’s 18 operating mines and 27 development projects in North, Central and South America; Australia; Europe and Africa produce gold, silver, palladium, platinum and cobalt.

Wheaton’s streaming advantage comes from investing in high quality assets with predictable production costs. As of July 2024, 93% of Wheaton’s current production comes from high margin mines operating in the lower half of their respective cost curves.

The company has contractually defined cost-per-ounce production agreements protecting it from inflationary cost pressures. This cost predictability, with delivery payments per ounce predetermined, translates into direct exposure to potential increases in precious metal prices, providing investors with some of the highest sustainable margins in the industry.

The company has entered into precious metals purchase agreements with 32 different mining companies for the purchase of precious metals and cobalt relating to 18 operating mining assets, in addition to 23 at various stages of development and four that have been placed in care and maintenance or have been closed. These mining assets are located across 16 countries.

Wheaton acquires mine production from its partners generally at or below the prevailing market price. The primary drivers of the company’s financial results are the volume of metal production at the various mining assets to which the precious metal purchase agreements relate and the price realized by Wheaton upon sale of the metals it receives.

Wheaton is actively pursuing future growth opportunities, primarily by way of entering into additional precious metal purchase agreements.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion. The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth.

This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council. In July 2024, the market price of gold was approximately $2,450 per ounce.

The Silver Institute, the association of the silver industry, reported in April 2024 that silver use in industrial applications set a new record high in 2023 at 654.4 million ounces (Moz). This figure excludes silver used in production of jewelry or in ornamental and decorative applications.

The institute reported that demand exceeded silver supply in 2023 for the third consecutive year, resulting in a structural market deficit of 184.3 Moz. Production of photovoltaic (solar energy) equipment is now the largest industrial use of the metal and is expected to continue its strong growth trend. In July 2024, the market price of silver was just over $29 per ounce.

Management Team

The company has an experienced management team with a strong track record of success and is well positioned for further growth.

Randy Smallwood is President and CEO of Wheaton Precious Metals and a Director. He previously served as the company’s Executive Vice President of Corporate Development. Prior to Wheaton Precious Metals, he was the Director of Project Development at Wheaton River Minerals Ltd. He formerly served on the boards of several resource companies including Defiance Silver, Ventana Gold, Castle Peak Resources and Tigray Resources. He holds a geological engineering degree from the University of British Columbia and a mine engineering diploma from the British Columbia Institute of Technology.

Gary Brown is Senior Vice-President and CFO of Wheaton Precious Metals. He previously was CFO of TIR Systems Ltd. and has also held senior finance roles with CAE Inc., Westcoast Energy Inc. and Creo Inc. He has more than 30 years of experience in finance and holds professional designations as a Chartered Professional Accountant and a Chartered Financial Analyst. He earned a master’s degree in accounting from the University of Waterloo.

Haytham Hodaly is Senior Vice-President of Corporate Development of Wheaton Precious Metals. He previously spent more than 16 years in the North American securities industry. Prior to that, he held the position of co-director of research and senior mining analyst at Salman Partners Inc. He is an engineer with a bachelor’s degree of applied science in mining and mineral processing engineering and a Master of Engineering, specializing in mineral economics, both from the University of British Columbia.

Wheaton Precious Metals Corp. (NYSE: WPM), closed Friday's trading session at $58.3, off by 0.7490637%, on 1,431,867 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $38.3738/$63.06.

Recent News

Annovis Bio Inc. (NYSE: ANVS)

The QualityStocks Daily Newsletter would like to spotlight Annovis Bio Inc. (NYSE: ANVS).

Annovis Bio Inc. (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). Annovis Bio stands out by developing a drug that targets multiple neurotoxic proteins simultaneously, aiming to restore axonal and synaptic activity. This innovative approach aims to treat memory loss and dementia associated with AD and body and brain dysfunction associated with PD, making Annovis a unique player in the neurodegeneration space.

Lead Drug Candidate: Buntanetap

Buntanetap (formerly Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying. Unlike monoclonal antibody therapies, Buntanetap is an orally available small molecule capable of inhibiting multiple neurotoxic proteins at once, positioning it as a comprehensive solution for neurodegenerative diseases.

In a recent Phase II/III Alzheimer’s study, Buntanetap demonstrated statistically significant efficacy. Patients with early AD showed a significantly higher rate of improvement in ADAS-Cog 11 scores across all treatment doses compared to placebo, with a -3.3 point improvement compared to -0.3 for placebo (p < 0.01). Plasma Tau protein levels also reduced, consistent with previous Phase II biomarker data, further validating Buntanetap’s mechanism of action.

Similarly, in the Phase III study of Buntanetap in patients with early Parkinson’s disease, significant advancements were observed. Topline data results are anticipated in June 2024. Preliminary findings indicate promising results in improving cognitive and motor function, underscoring Buntanetap’s potential as a transformative therapy for Parkinson’s disease.

Market Opportunity

The aging population presents a significant market opportunity, with nearly 7 million Americans currently suffering from Alzheimer’s Disease (AD), a figure projected to rise to almost 13 million by 2050 (Alzheimer’s Association) (Republican Policy Committee). Additionally, approximately 1.2 million people in the U.S. have Parkinson’s Disease (SingleCare).

The economic burden of Alzheimer’s is immense, with care costs expected to reach $360 billion in 2024 and escalate to nearly $1 trillion annually by 2050. The need for effective, comprehensive treatments like Buntanetap is more critical than ever.

Company Highlights

  • Innovative Therapeutic Approach: Annovis Bio uniquely targets multiple neurotoxic proteins, aiming to restore nerve cell health and improve cognitive and motor function in AD and PD patients.
  • Robust Clinical Data: Phase II/III studies show significant improvements in cognitive function and biomarker levels in early AD patients.
  • Groundbreaking Clinical Insights: Preliminary results from Phase II studies indicate significant improvements in motor functions and speed in patients with Parkinson’s Disease (PD).
  • Upcoming Phase III Trials: Plans are underway for an 18-month Phase III trial focusing on biomarker-positive early AD patients, designed to further validate Buntanetap’s disease-modifying potential.
  • Capital Efficiency: Annovis Bio is capital-efficient, with zero debt and multiple global patents extending into the 2040s.

Management Team

Maria L. Maccecchini, Ph.D., Founder, President, CEO, and Executive Board Member, founded Annovis Bio in May 2008 with the mission to develop better therapeutics for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. She has previously been a partner and director at two angel groups, Robin Hood Ventures and MidAtlantic Angel Group, and founded Symphony Pharmaceuticals/Annovis, which was sold to Transgenomic in 2001. Her extensive experience includes roles such as General Manager at Bachem Bioscience and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini holds a Ph.D. in biochemistry from the Biocenter of Basel, with postdoctoral work at Caltech and the Roche Institute of Immunology.

Cheng Fang, Ph.D., Senior VP of Research and Development, is an accomplished neuroscientist with two decades of experience in neurodegenerative diseases. She has a successful track record of scientific publications and contributions, coupled with extensive pre-clinical and clinical development experience. Dr. Fang has been instrumental in advancing the understanding of neurodegenerative disease mechanisms and developing therapeutic strategies.

Michael Christie, Ph.D., VP of Process Chemistry, has over 40 years of experience in the pharmaceutical industry, focusing on process chemistry R&D, pilot plant production, and GMP operations. He has held senior management positions at companies such as SmithKline, Rhodia, Teva, and Cephalon, and founded a contract process R&D service company, which was later acquired by ChiRex. Dr. Christie is co-author or co-inventor on several publications and patents. He earned his BS in chemistry from the University of Michigan and his doctorate from MIT.

Melissa Gaines, Senior VP of Clinical Operations, is an accomplished clinical research professional with over 20 years of experience across academia, contract research organizations, and pharmaceutical companies. She has proven abilities in monitoring and managing Phase I to IV clinical trials, specializing in CNS disorders and extending to a broad range of therapeutic indications. Her CNS experience spans from small Phase I and II studies to large global Phase III trials in Alzheimer’s disease, Parkinson’s disease, sleep disorders, and various psychiatric diseases in both adult and pediatric populations. In her current role, she oversees and supports all clinical project activities, driving operational success and ensuring high-quality clinical outcomes.

Learn more about the Annovis Bio team on LinkedIn.

Annovis Bio Inc. (NYSE: ANVS), closed Friday's trading session at $10.96, up 4.68%, on 371,904 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.53/$22.49.

Recent News

McEwen Mining Inc. (NYSE: MUX) (TSX: MUX)

The QualityStocks Daily Newsletter would like to spotlight McEwen Mining Inc. (NYSE: MUX) (TSX: MUX).

McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) is an asset rich diversified gold and silver producer in the Americas with a large exposure to copper through its subsidiary, McEwen Copper, owner of the Los Azules copper deposit in Argentina, believed to be the 8th largest undeveloped copper resource in the world.

Led by a management team with a track record of success, MUX owns and operates mines in some of the most prolific gold producing regions of the Americas. The company proactively took cost-saving measures months ago to lower expenses and increase production across its portfolio of gold assets, driving some production costs below industry averages. Gold and copper prices, already in an upswing, are forecast to enter an explosive uptrend over the next couple years. Drawing from its experience, McEwen Mining planned, prepared and laid the groundwork to capitalize on this emerging opportunity.

The company currently holds a Zacks Rank #1 (Strong Buy), placing it in the top 5% of over 4,000 stocks ranked by Zacks, based on trends in earnings estimate revisions and EPS surprises. Seldom is management so aligned with investors’ interests and committed to the company’s success. With a combined investment of over $220 million, CEO Rob McEwen holds a 17% ownership stake in McEwen Mining and a 13% ownership in McEwen Copper. Acclaimed in the mining industry, McEwen founded Goldcorp, where he increased the company’s market capitalization 160 times – from $50 million to over $8 billion. That same vision and tenacity led MUX in creating McEwen Copper.

For McEwen Mining shareholders, beyond the company’s exposure to gold upsurges, its 47.7% stake in McEwen Copper is expected to be a blockbuster, turbocharging MUX by creating the world’s next prolific copper unicorn.

McEwen Copper

With continuous industrial need, new critical demand for copper is rapidly emerging, increasingly driven by the green energy transition. The price of copper rose from a low of about $2 per pound in 2020 to over $4.60 per pound in May 2024, and strong demand is expected to intensify. A study by S&P Global, titled The Future of Copper: Will the Looming Supply Gap Short-circuit the Energy Transition?, projects global copper demand to nearly double over the next decade, from 25 million metric tons today to about 50 million metric tons by 2035. Based on current trends, S&P Global forecasts annual supply shortfalls to reach nearly 10 million metric tons in 2035.

McEwen Mining owns a 47.7% equity stake in McEwen Copper, the holder of a 100% interest in the Los Azules copper project in San Juan, Argentina, which is ranked the 8th largest undeveloped copper deposit in the world. Current copper resources at Los Azules are estimated at 10.9 billion pounds at a grade of 0.40% Cu (Indicated category) and an additional 26.7 billion pounds at a grade of 0.31% Cu (Inferred category). McEwen Copper also owns a copper exploration project in Nevada, USA, called Elder Creek.

In a 2023 Preliminary Economic Assessment (PEA), Los Azules was estimated to have a 27-year life, producing an average of 322 million lbs. of copper cathode annually, at a cash cost of $1.07 per lb. of copper, in the lowest quartile of the copper cost curve. The project could ultimately become an even larger mine with a longer life, since the extent of mineralization has not been fully assessed on the property.

The project’s 2023 PEA presents a distinctly different development strategy from a prior PEA published in 2017. By proposing a heap leach project using solvent extraction-electrowinning instead of the previously detailed mine with a conventional mill and flotation concentrator, McEwen Copper aims to decrease its environmental footprint and reduce permitting risk, albeit with a lower overall copper recovery, slightly higher unit costs and a delay in immediate cashflow due to extended leach cycles.

After securing a $25 million investment from mining giant Rio Tinto’s technology arm, Nuton LLC, McEwen Copper closed its non-brokered, private placement offering of $82 million in August 2022. Shortly after, in February 2023, Nuton agreed to invest an additional $30 million into McEwen Copper, and in October 2023, Nuton once again expanded its stake, investing an additional $10 million to bring its ownership position in McEwen Copper to 14.5%.

“We are extremely pleased to have Nuton’s strong continued participation in McEwen Copper,” Rob McEwen stated in a news release. “Together we are exploring new technologies that save energy, water, time and capital in the pursuit of delivering green copper to Argentina and the world, a product that will contribute to the electrification of transportation and the protection of our atmosphere.”

Also in February 2023, FCA Argentina S.A., a subsidiary of Stellantis N.V., one of the world’s leading automakers, invested ARS $30 billion in McEwen Copper. In October 2023, Stellantis invested an additional ARS $42 billion, bringing its current stake in McEwen Copper to 19.4%.

“We are delighted to have Stellantis as a partner in the future development of our Los Azules copper project,” Rob McEwen said of the investment. “Together, we share a vision to build a mine for the future based on regenerative principles that can achieve net-zero carbon emissions by 2038.”

Following the capital raise, McEwen Copper is well-funded to advance its Los Azules Project, with a Feasibility Study planned for Q1 2025. MUX strategically reduced its interest to increase its treasury, in order to reduce debt and fund the further development of its gold and silver assets.

Gold & Silver Projects

The Fox Complex

McEwen Mining owns a 100% stake in the Fox Complex in the heart of a prolific gold district in Timmins, Canada.

“When MUX bought the Fox Complex, in late 2017, it was a distressed asset with a history of high operating cost/oz. While it has taken longer than I expected, the cost to produce an ounce of gold is significantly lower,” CEO Rob McEwen stated in a news release.

McEwen Mining issued 2024 guidance for its cash cost/oz at the Fox Complex of $1,225-1,325 on annual production of 40,000-42,000 GEOs. Fox Complex produced 44,450 GEOs in 2023, which was within the company’s guidance range.

Located in one of the most prolific gold production areas in the world, along the Destor-Porcupine Fault Zone within the Abitibi Greenstone Belt, the Fox Complex includes the Black Fox mine and Froome mine which together have yielded over 1,000,000 ounces of gold to date. Also, the complex includes the Grey Fox and Stock deposits that have over 1,800,000 ounces in gold resources. The 2.7-billion-year-old Abitibi Greenstone Belt, formed by ancient volcanic activity, has proved to be one of the world’s richest and most abundant gold regions, with a total gold content currently estimated at over 300 million ounces.

In 2024, MUX commenced development of underground ramp access to the Stock orebodies at the Fox Complex. This development will become the primary source of feed following the completion of mining the Froome deposit in 2026. As part of the future mining sequence initiative, the company has already reported a 31% year-over-year increase of gold resources at Stock West and Stock Main (historical Stock Mine), with confirmation of good grading structures plunging to depth. It has also identified Stock East as a potential new near-term source of future revenue.

The Gold Bar Mine

McEwen Mining owns a 100% stake in the Gold Bar mine, located in an area well known for gold production, the southern Roberts Mountains of the Battle Mountain-Eureka-Cortez gold trend in Eureka County, Central Nevada. The Gold Bar mine is on the same geological structure, 25 miles south of Nevada Gold Mines, a Barrick-Newmont joint venture, part of the Cortez-Goldrush complex. This complex contains estimated reserves and resources of over 50 million gold ounces, with an annual production of 1,000,000 gold ounces.

Gold Bar had been mined between 1991 and 1994, producing 134,000 gold ounces. A new facility was built by MUX in 2019. Gold Bar accounted for 42,700 GEOs in 2023, within the company’s guidance for the year. For 2024, McEwen Mining issued guidance of 40,000-43,000 at a cash cost of $1,450-1,550. The first half of the year is expected to deliver higher production relative to the second half, due to a scheduled waste stripping phase in the Pick pit, in preparation for the 2025 mining program.

Notably, in April 2024, McEwen Mining announced its entry into a definitive agreement and plan of merger with Timberline Resources Corporation (TSX.V: TBR) (OTCQB: TLRS) in a transaction valued at roughly $18.8 million. The merger with Timberline is expected to augment McEwen’s existing portfolio of development and exploration projects in Nevada, leveraging synergies between Timberline’s projects and the Company’s Gold Bar mine.

El Gallo/Fenix

Project Fenix is the proposed redevelopment plan for McEwen Mining’s El Gallo Complex in Mexico. There is a long history of mining in this region. MUX began operating it as an open pit, heap leach mine in 2013, which produced 281,000 gold equivalent ounces at average cash cost of $655 per ounce. Due to the transition to deeper sulfide mineralization that is not amenable to heap leaching, mining activities ceased in the second quarter of 2018 and residual heap leaching followed until mid-2022. The redevelopment plan envisions constructing a mill at the existing mine site that will initially reprocess the existing heap leach material, then transition to open pit mining and processing of the sulphide mineralization. The company recently acquired a complete process plant on very advantageous terms that has considerably reduced the projected capital requirements for the project.

CEO Rob McEwen stated in a news release, “This acquisition has made Fenix more attractive to build and could provide a new long life mine for McEwen Mining.”

The initial development approach is to build a mill to reprocess the material on the heap leach pad and produce approximately 17,000 oz of gold annually for eight years. Construction of the Fenix project is expected to begin in the second half of 2024.

San José Mine

McEwen Mining is a 49% owner and non-operator of the San José gold and silver mine, located in Santa Cruz province, Argentina, encircling Newmont’s prolific Cerro Negro (approx. 300,000 gold ounces produced in 2023). This high-grade underground mine has been operating since 2007 and currently has an expected life of six years with a reserve grade of 296 gpt silver and 5.4 gpt gold.

Exploration is continuing to extend high-grade veins and discover new veins at the complex. San José’s drilling programs to define additional resources and reserves have a long history of success due to a high vein density, aided by good geophysical response from hidden veins.

Production guidance for 2024 for MUX’s 49% interest is 50,000-60,000 GEOs. As a minority shareholder in the mine, MUX equity accounts for its investment in San José, and receives 49% of the dividends from the mine’s free cash flow.

Market Outlook

Mining stocks suffered significant losses in the wake of the COVID-19 pandemic. However, this has turned, and many analysts now forecast a gold bull market in 2024 and beyond.

“The operating challenges we faced in recent years have severely damaged our credibility with our shareholders and the market. As a result, few investors have taken a close look recently at our assets,” Rob McEwen said in a news release. “If they did, I believe some would see the potential value that I see today… I believe there is considerable potential value in MUX, and that is a big reason why I have a personal financial commitment of $220 million in MUX and McEwen Copper.”

Management Team

Robert R. McEwen is Chairman, CEO and Chief Owner of McEwen Mining. He has been associated with the gold industry all his career, with his first 18 years in the investment industry and, since 1990, as CEO of several gold mining companies. He founded Goldcorp and took that company from a $50 million market capitalization to more than $8 billion. He owns 17% of McEwen Mining and is in complete alignment with investors – his investment in MUX and McEwen Copper is $220 million and he takes an annual salary of only $1. He was awarded the Order of Canada and the Queen Elizabeth’s Diamond Jubilee Award, was inducted into the Mining Hall of Fame, was named an Ernst and Young Entrepreneur of the Year and has Honorary Doctor of Law degrees from York University and Western University.

William Shaver is interim COO and a Director of McEwen Mining. He has decades of management and executive experience in mine design, construction and operations. He was a founder of Dynatec Corporation, which became one of the leading contracting and mine operating groups in North America. In 2013, he was recognized as Ernst and Young Entrepreneur of the Year. Most recently, he served as COO of INV Metals. He is a Professional Engineer with a B.Sc. in Mining Engineering from Queens University.

Perry Ing is interim CFO at McEwen Mining. He has 25 years of experience in the Canadian mining industry. Over the past 15 years, he has held positions as CFO of Mountain Province Diamonds, Kirkland Lake Gold and McEwen Mining. Prior to that, he worked at Barrick Gold and Goldcorp and started his career in the mining practice at PwC. He has a Bachelor of Commerce from the University of Toronto and is a Chartered Professional Accountant in Canada and Certified Professional Accountant in the U.S.

Adrian Blanco S. is the company’s Director of Operations for America and Mexico. He has extensive international experience in several industrial sectors and has held executive positions in Mexico, the United States, Peru and Argentina. He joined the McEwen Mining team in 2015 and has led a successful business transformation toward operational discipline, best business practices and financial profitability at subsidiaries Compañia Minera Pangea and McEwen Mining Nevada. He graduated from an Executive Management Program at IPADE and Harvard Business School.

Michael Meding is Vice President and General Manager of McEwen Copper. He has over 20 years of international experience, primarily with major mining companies such as Barrick Gold and Trafigura, including extensive experience with project development and operations in Argentina. While at Barrick Gold’s Veladero mine in Argentina, Mr. Meding played a key role in the turnaround, extension of the mine life and subsequent strategic partnering with Shandong Gold. He holds an MBA from Indiana University in Pennsylvania and an MBA from the Leipzig Graduate School of Management in Germany.

McEwen Mining Inc. (NYSE: MUX), closed Friday's trading session at $9.12, off by 0.7616975%, on 527,587 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $5.92/$12.50.

Recent News

Nightfood Holdings Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings Inc. (OTCQB: NGTF).

Nightfood Holdings Inc. (OTCQB: NGTF) is a visionary holding company focused on identifying and capitalizing on explosive market trends within hospitality, food services and consumer packaged goods. By leading newly emerging categories and seizing opportunities in markets undergoing transformational upheaval, the company’s mission is to create unparalleled upside potential in industries ripe for innovation and growth.

Subsidiaries

Nightfood Inc.

The company’s flagship subsidiary, Nightfood Inc., is changing the way the world snacks at night. Humans are biologically hard-wired to crave sweets and fats at night – a survival mechanism from our hunter-gatherer days. Modern consumers know bingeing excess calories before the long nightly fast is no longer necessary for survival, but exploding screen time and decreased willpower at night results in over 90% of American adults snacking between dinner and bed every week, contributing to an estimated one billion nighttime snack occasions weekly (according to SleepFoundation.org).

The most popular choices – ice cream, cookies, chips and candy – are not only unhealthy but also impair sleep quality due to their nutritional profiles. Nightfood snacks are uniquely formulated by sleep and nutrition experts to satisfy nighttime cravings AND support better sleep.

Market Opportunity

Euromonitor International projects the American snack market will grow from $150 billion in 2022 to $170 billion in 2027. Snacking between dinner and bed is estimated to account for over $60 billion annually, creating an opportunity for a multi-billion-dollar sub-category to emerge in the coming years: sleep-friendly snacking.

Nightfood is the brand pioneering that category.

Nightfood’s innovation has led to partnership overtures from global giants, including the largest food and beverage company in the world, Nestlé, with whom Nightfood completed a “test-and-learn” joint initiative in 2023.

Management believes that successfully scaling Nightfood’s 2024 direct-to-consumer launch of sleep-friendly cookies will bring the category to life, opening the door for partnerships with and potential acquisition by global snack giants seeking to lead this potential billion-dollar emerging sub-category.

Future Hospitality Ventures Holdings Inc. (d/b/a roboOp365)

Future Hospitality Ventures Holdings, operating under the brand roboOp365, is revolutionizing the hospitality industry with cutting-edge automation and robotic solutions.

roboOp365 enhances operational efficiency and guest experiences through innovative technologies, including automated culinary bot, server robots and AI-enhanced applications. roboOp365 helps hospitality providers reduce costs, streamline operations and deliver superior service by integrating these advancements.

Market Opportunity

The robots-as-a-service (RaaS) business model has gained significant traction, super-charged by the COVID-19 pandemic, which instantly catalyzed game-changing growth and application. According to Verified Market Research, the service robotics market is projected to reach $173.17 billion by 2030, growing at a compound annual growth rate (CAGR) of 21.25%. Compared to Asia, the United States market is in the early stages of adopting these technologies, but acceptance is accelerating aggressively.

Several factors are driving this trend. Key industries such as hotels and restaurants are still struggling to rebound from the pandemic’s impact, hoping to return to pre-pandemic levels, if possible. Such recovery will largely be dependent upon service robots. In California specifically, factors such as rising labor costs, more rigorous labor laws and ongoing high turnover rates in labor-intensive sectors make it impossible for businesses to survive, thrive and compete without robotics.

Innovation Across Sectors

Nightfood Holdings Inc. is dedicated to driving innovation across its focus sectors of food services, automation and hospitality applications. In food services, the company leverages automation technology to drive operational efficiency for operators while meeting evolving consumer needs. In the hospitality industry, it’s deploying solutions that redefine guest experiences. Nightfood’s consumer-packaged goods initiatives are key to breakthrough trends in health and wellness.

Synergizing Food and Technology

The synergy of food and technology within Nightfood Holdings Inc. creates a holistic approach to innovation and automation. By integrating these areas, the company offers comprehensive solutions that address multiple facets of market needs. Its automation and artificial intelligence solutions in food service and hospitality create a seamless and enhanced consumer experience.

Through this integrated approach, Nightfood Holdings Inc. not only meets current market demands but also anticipates and influences future trends, positioning itself as a leader in innovation across these interconnected sectors. Synergies in these related and explosive categories result in operational efficiency and benefits for the company’s customers and partners and outsized upside and opportunity for its investors.

Management Team

Sean Folkson is the Chairman and President of Nightfood. He founded Nightfood when he couldn’t find a solution to his nighttime snacking problem. Recognizing the growing body of research linking nutritional intake with sleep quality, he launched the first snack brand specifically formulated to give consumers better, healthier and more sleep-friendly snacks for that peak-cravings slot between dinner and bed. He is a serial entrepreneur and problem-solver, having previously founded Specialty Equipment Direct, an online distributor of floor removal equipment, and AffiliatePros.com, a pioneering company in online affiliate marketing.

Lei Sonny Wang is the CEO of Nightfood Holdings. He is a strategist and business driver for early-stage and growth-stage companies. He is the founder and former CEO of Future Hospitality Ventures Holdings Inc., which was acquired by Nightfood Holdings Inc. At Future Hospitality, he leveraged his significant international business development experience into distribution relationships with leading global robotics manufacturers. At Nightfood, he is working to grow revenue and improve performance and profitability across all subsidiaries.

Nightfood Holdings Inc. (OTCQB: NGTF), closed Friday's trading session at $0.03, up 27.1186%, on 303,423 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0075/$0.0425.

Recent News

PaxMedica Inc. (NASDAQ: PXMD)

The QualityStocks Daily Newsletter would like to spotlight PaxMedica Inc. (NASDAQ: PXMD).

PaxMedica Inc. (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (APTs) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms.

The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself.

PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main energy molecule in all living cells.

The company is headquartered in Tarrytown, New York.

Product Pipeline

PaxMedica is building a robust pipeline of products targeting ASD and related neurodevelopmental conditions. The company’s lead product in development may help eliminate, reduce or modulate some of the more troublesome aspects of ASD. That would open the potential for people with autism to integrate their behavior with others more successfully and improve their lives.

PaxMedica’s lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting anti-purinergic therapy that has been known for over 100 years. Its current pipeline includes:

  • PAX-101 (IV Suramin) for ASD – PAX-101 completed a Phase 2B study for ASD in 2021. Suramin is a broadly acting APT and has reported positive results from a dose range study. The results of PaxMedica’s Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021.
  • PAX-102 (Intranasal Suramin) – PaxMedica has developed a proprietary intranasal formulation of suramin that is currently being evaluated in ASD and other neurodevelopmental conditions.
  • PAX-101 for HAT – Given suramin’s historical use as a treatment for Human African Trypanosomiasis (HAT), or African Sleeping Sickness, the company is also developing PAX-101 as a treatment for HAT. PaxMedica’s most advanced program is the pursuit of PAX-101 for early-stage East African HAT.
  • Selective APTs – PaxMedica has conducted several preclinical studies to evaluate other APTs that are more selective to specific purinergic receptors and may offer additional benefits over suramin.

Market Opportunity

According to a report by Fortune Business Insights, a leading global market research company, the global ASD therapeutics market was estimated at $1.93 billion in 2022 and is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, a CAGR of 7.9% over the forecast period. As there is no current treatment for the core symptoms of autism, PaxMedica believes the addressable market for PAX-101, if approved, could greatly exceed these forecasts.

Autistic disorder, Asperger’s Syndrome and Pervasive Development Disorder are the three main types of ASD, affecting millions of people globally. A 2020 report by the U.S. Centers for Disease Control & Prevention estimated that one in 36 children in the U.S. have been diagnosed with autism disorder.

Several factors are expected to contribute to market growth prospects. A growing prevalence of the condition globally and rising awareness coupled with available treatment options are key factors expected to drive ASD therapeutics market growth during the forecast period. Growing investment in R&D to find effective treatments is also expected to fuel global market growth.

Management Team

Howard Weisman is Chairman and CEO of PaxMedica. He has been a founder and CEO of several specialty pharma and medical device companies. Most recently, he was executive chairman and co-founder of Sofregen, a biotech company. He also served as CEO and president of Seventh Sense Biosystems, a medical device development company. He also was founder, chairman and CEO of EKR Therapeutics, a specialty pharmaceutical company, and founder and COO of ESP Pharma, a company focused on cardio and neurovascular products. He has a bachelor’s degree in chemistry from Rutgers University.

David Hough, M.D., is Chief Medical Officer at PaxMedica. He is a neuroscience clinical development consultant who previously served as vice president at Janssen Research and Development and in various leadership roles over 17 years. Most recently, he was the compound development team leader for SPRAVATO® for treatment-resistant depression. Prior to that, he was the schizophrenia disease area leader. He played a pivotal role in the development programs for oral INVEGA®, INVEGA SUSTENNA® and XEPLION® for schizophrenia. He is a graduate of West Point and is board certified in psychiatry.

Stephen Sheldon is COO and CFO at PaxMedica. He has served as CEO of Thailand-based specialty healthcare company Indochina Healthcare Co. Ltd. since 2015. Previously, he was a consultant for PricewaterhouseCoopers Healthcare Advisory in the Chicago office. He was responsible for developing specialty pharmacy patient programs, strategy development for specialty products and compliance programs. He has an MBA from Thunderbird School of Global Management and a bachelor’s degree in computer science and visual arts from Bowdoin College.

PaxMedica Inc. (NASDAQ: PXMD), closed Friday's trading session at $0.28, up 15.2263%, on 201,140 volume. The average volume for the last 3 months is 85,598 and the stock's 52-week low/high is $0.20/$12.9217.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has also collaborated with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has been granted patent protection for specific delivery of nicotine, vitamins, NSAIDs, antiviral drugs, cannabinoids and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Friday's trading session at $3.38, up 9.3851%, on 201,526 volume. The average volume for the last 3 months is 221,508 and the stock's 52-week low/high is $0.7598/$6.85.

Recent News

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF)

The QualityStocks Daily Newsletter would like to spotlightFathom Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF).

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) is a publicly traded Canadian minerals exploration company focused on exploring high-grade copper and gold deposits in North America. The company owns the Storm Copper Project and the Seal Zinc Deposit in Nunavut, Canada, and is currently exploring the Buckingham Gold Vein and critical metals prospects in central Virginia. Aston Bay is also in the advanced stages of negotiation on other properties with high-grade critical minerals potential in these areas.

The company believes in responsible exploration and carries out its work programs to the highest standards of social responsibility, environmental stewardship and health and safety. Aston Bay cares about leaving a net positive impact on the communities in which it works and engages with local representatives, Indigenous groups and government agencies to build respectful relationships through dialogue and collaborative processes. Depending on the stage of exploration, these efforts may include employment, contracting, training, community benefits and other agreements.

Aston Bay conducts exploration through safe, socially and environmentally responsible and sustainable work practices. The company embeds core values of health and safety throughout its operations by adhering to strict health and safety standards and practices that meet and/or exceed industry standards and government codes and regulations.

The company is headquartered in Toronto.

Projects

Storm Copper

The high-grade Storm Copper Deposit is located 112 kilometers south of the community of Resolute Bay, Nunavut, on western Somerset Island, just south of the past-producing Polaris Pb-Zn Mine. The property comprises 173 contiguous mining claims, including the Storm Copper and Seal Zinc projects, covering an area of approximately 541,795 acres.

The property has good access to established shipping lanes, and the landscape provides favorable conditions for development of roads and a protected deep-water port. Exploration is supported through excellent infrastructure in the nearby hamlet of Resolute Bay.

Aston Bay is partnered with American West Metals (ASX: AW1) at Storm. American West is responsible for all exploration expenditures, having aggressively advanced the project toward production and earned an 80% interest. This affords excellent optionality to the company’s shareholders, as Aston Bay is free carried with no required expenditures until the completion of a bankable feasibility study.

American West recently completed an Australian JORC-compliant Maiden Resource Estimate for Storm; the North American 43-101 compliant resource estimate is expected in Q1 2024. American West is cashed up and plans a multimillion-dollar resource expansion and new discovery drilling program for the summer of 2024.

The Buckingham County Gold Project

The gold-bearing system at the Buckingham County Gold Project in Virginia lies within a belt hosting past producing mines, current gold mines and advanced gold explorations, stretching through Georgia, the Carolinas, Virginia, Nova Scotia and Newfoundland.

Buckingham hosts a “Kirkland Lake-style” high grade gold vein returning values consistently over one ounce gold per ton and is underexplored both at depth and along almost one mile of strike length. These types of veins have excellent ESG qualities, as they are typically mined using a small footprint underground method, with gold extracted using simple and environmentally friendly gravity methods.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion. The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth.

This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

A report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Thomas Ullrich is CEO and Director of Aston Bay. He has over 30 years of experience in mineral exploration and geoscience. Before joining Aston Bay, he was Chief Geologist North America for Antofagasta Minerals plc, investigating copper potential through extensive property evaluations and management of drill programs in the United States, Mexico and Canada. Prior to that, he was Senior Geologist for Almaden Minerals.

Sofia Harquail handles Investor Relations and Corporate Development at Aston Bay. She has over 15 years of experience in the private and public sectors of the mining industry. Before joining Aston Bay, she worked as a consultant for the Prospectors and Developers Association of Canada and for exempt market dealer Red Cloud Financial Services Inc. Ms. Harquail holds an M.A. from the University of Uppsala in Sweden and received her CPIR designation from the CIRI/Ivey Investor Relations Program. She also sits on the board of the Young Mining Professionals Toronto and is CSC Certified.

Aston Bay has a talented Board of Directors bringing broad experience from across the industry, encompassing resource expansion, mine development, mergers and acquisitions, and mining finance.

Ms. Jessie Liu-Ernsting has over 15 years of experience in the mining industry, spanning capital projects engineering, debt capital markets, private equity and corporate strategy at several firms, including Hudbay Minerals and Resource Capital Funds. She is currently VP Investor Relations and Communications at G Mining Ventures Corp.

Mr. Jeffrey R. Wilson has over 25 years’ experience in the mining industry, having served as a director, officer and advisor of multiple public and private companies in the mineral exploration and mining investment industries. Mr. Wilson is currently President & CEO of Precipitate Gold Corp.

Mr. Gary O’Connor has over 40 years of diverse experience as a mineral exploration and development professional in the management of successful resource projects as well as the evaluation, technical due diligence, and supervision of large mineral exploration and development projects through-out the world. While with Freeport, Mr. O’Connor worked on the due diligence and discovery of a major gold fraud on the Busang gold “deposit” in Kalimantan by Bre-X.

Mr. Mark J. Pryor is a geologist with a 40-year track record of successfully advancing multiple precious metal, copper, coal, REE and Li projects from discovery through to exploitation. He is currently Executive Vice President of the Exploration Division at The Electrum Group.

Aston Bay Holdings Ltd. (OTCQB: ATBHF), closed Friday's trading session at $0.0799, up 2.6333%, on 1,000 volume. The average volume for the last 3 months is 36,223 and the stock's 52-week low/high is $0.0268/$0.2474.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.